AzTrials
AzTrials

PneumoniaNCT00435305

Steady State Serum and Epithelial Lining Fluid (ELF) Antibiotics Concentrations Under Continous Infusion

An observational study of Pneumonia and Bacteremia, run by University Hospital Tuebingen at 1 site in Germany.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The purpose of our study is to determine the penetration of continuously infused antibiotics at steady state, mainly Meropenem, Vancomycin, Linezolid, Piperacillin/tazobactam and additionally cefepim and ceftazidim, into epithelial lining fluid. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Pneumonia, Bacteremia
What is being tested?
Meropenem, Vancomycin and Linezolid
How many people
40 participants
Where
1 siteGermany
Study dates
Nov 2006to Nov 2007
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients of both gender >0 18 years of age
  • Patients of an ICU with one or more of the following infections
  • Bacteremia. sepsis
  • pneumonia
  • tracheo-bronchitis
  • mechanical ventilation
  • stay on the ICU >= 3 days
  • indication for bronchoscopy

Who cannot join

  • pregnancy
  • allergy against the studied drug
  • known resistance of the involved pathogen against the study drug
  • simultaneous participation in other studies
  • former participation in the present study
  • probable stay on the ICU < 3 days
  • contra-indication against the study-drug
  • contra-indication for bronchoscopy

Trial locations and contacts

1 site in 1 country.

Germany1 site
  • Universitäsklinikum Tübingen, Klinik für Anästhesiologie und Intensivmedizin

    Tübingen, 72076

Other trials in Germany

About this study

Official title: Antibiotic Concentrations in Serum and Epithelial Lining Fluid Under Continous Infusion

The purpose of our study is to determine the penetration of continuously infused antibiotics at steady state, mainly Meropenem, Vancomycin, Linezolid, Piperacillin/tazobactam and additionally cefepim and ceftazidim, into epithelial lining fluid.

Read the detailed description

Severe infectious disease may be the cause for admitting a patient to an ICU, but more often they constitute a complication of the intensive care and turn out to be caused by nosocomial pathogens.

Nosocomial infections are associated with a high lethality. The appropriate antibiotic therapy determines in part the outcome of the patients. Especially this antibiotic therapy implicates a number of problems for the physician.

He has to ensure that the chosen antibiotics are effective against the most common and presumed pathogens and that the reached concentrations of antibiotics in plasma and epithelial lining fluid are reliably and permanently above the minimal inhibitory concentration (MIC) for the given pathogens.

All the antibiotics included in our clinical trial are so called "time dependent" antibiotics. They are most effective if there concentrations reach a certain level (MIC) at the infected site (epithelial lining fluid in our study) over the entire period of treatment.

To achieve this aim, many authors already suggested that the continuous infusion might solve the problem of too low antibiotic plasma and ELF levels. Studies about pharmacokinetics of continuous infused antibiotics, which were conducted in healthy volunteers or patients with normal organ function, cannot be assigned to critical ill patients. Rationales for this statement are that data about plasma and tissue levels of antibiotics in critical ill patients are highly influenced by modified volume of distribution, elimination half-life period and impaired tissue perfusion compared to healthy volunteers. These physiological variances implicate that the response to the antibiotic treatment remains doubtful. Under these pathophysiological conditions, data about antibiotics plasma and ELF levels may provide additional information in order to adjust the dosing regime of antibiotics.

Studies conducted in critical ill patients showed that under the circumstances of continuous infused antibiotics, the reached levels in plasma are above the MIC. However there is little data about penetration into ELF of continuous infused antibiotics.

Our study intends to provide data about plasma and ELF levels of continuous infused antibiotics in steady state, determine a penetration coefficient for these antibiotics into ELF and to compare the reached levels in ELF to the MIC.

To demonstrate the efficiency of continuous infused antibiotics, we will conduct quantitative microbiological measurements before and after treatment if applicable.

Being tested
Meropenem, Vancomycin, Linezolid, Piperacillin/Tazobactam, Cefepim
Keywords
continuous infusion, epithelial lining fluid, antibiotics, pneumonia, critical illness
Medical subject headings
Pneumonia, Bacteremia, Critical Illness

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • MeropenemDrug

  • VancomycinDrug

  • LinezolidDrug

  • Piperacillin/TazobactamDrug

  • CefepimDrug

  • CeftazidimDrug

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Feb 2007 (estimated)
  2. Study startNov 2006
  3. Study completionNov 2007 (estimated)

Why it stopped: difficulties by enrolling patients fundings consumed, no staff could be recruited and payed to continue enrolling patients,

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Time perspective
Prospective
Enrolment
40 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00435305
Sponsor's protocol ID
2005-002128-32
Other IDs
2005
Status last verified
Jun 2008
First submitted
13 Feb 2007
Last updated
9 Jun 2008
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

An observational study of Pneumonia and Bacteremia, run by University Hospital Tuebingen at 1 site in Germany.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 9 Jun 2008. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: difficulties by enrolling patients fundings consumed, no staff could be recruited and payed to continue enrolling patients,). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jun 2008.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in